|
MechanismHMG-CoA reductase inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date30 Aug 2019 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A randomized, open-label, multiple dosing, crossover study to evaluate the pharmacokinetic drug-drug interaction and safety between nebivolol and rosuvastatin in healthy male volunteers
A randomized, open-label, single dose, 2-way crossover study to evaluate the pharmacokinetic characteristics of EL-1401 in comparison to the co-administration of nebivolol and rosuvastatin in healthy volunteers
A randomized, open-label, single dose, crossover clinical study to investigate the effect of food on the pharmacokinetics of EL-1804 in healthy adult subjects
100 Clinical Results associated with Elyson Pharm Co., Ltd.
0 Patents (Medical) associated with Elyson Pharm Co., Ltd.
100 Deals associated with Elyson Pharm Co., Ltd.
100 Translational Medicine associated with Elyson Pharm Co., Ltd.